A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Lorlatinib (Primary) ; Crizotinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms CROWN
- Sponsors Pfizer
- 24 Jul 2017 Planned End Date changed from 12 Aug 2023 to 23 Oct 2023.
- 24 Jul 2017 Planned primary completion date changed from 11 Dec 2019 to 17 Feb 2020.
- 06 Jun 2017 Planned primary completion date changed from 4 Dec 2019 to 11 Dec 2019.